Currently, there are 2.53B common shares owned by the public and among those 2.53B shares have been available to trade.
The company’s stock has a 5-day price change of -0.04% and -14.35% over the past three months. MRK shares are trading 0.65% year to date (YTD), with the 12-month market performance up to 6.06% higher. It has a 12-month low price of $99.14 and touched a high of $134.63 over the same period. MRK has an average intraday trading volume of 9.46 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.25%, -4.19%, and -10.63% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Merck & Co Inc (NYSE: MRK) shares accounts for 79.06% of the company’s 2.53B shares outstanding.
It has a market capitalization of $278.14B and a beta (3y monthly) value of 0.40. The stock’s trailing 12-month PE ratio is 20.34, while the earnings-per-share (ttm) stands at $5.40. The company has a PEG of 0.84 and a Quick Ratio of 1.22 with the debt-to-equity ratio at 0.87. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.76% over the week and 1.60% over the month.
Earnings per share for the fiscal year are expected to increase by 420.23%, and 23.33% over the next financial year. EPS should grow at an annualized rate of 24.25% over the next five years, compared to -42.70% over the past 5-year period.
Looking at the support for the MRK, a number of firms have released research notes about the stock. Societe Generale stated their Sell rating for the stock in a research note on March 11, 2024, with the firm’s price target at $104. TD Cowen coverage for the Merck & Co Inc (MRK) stock in a research note released on January 04, 2024 offered a Outperform rating with a price target of $135. Deutsche Bank was of a view on November 09, 2023 that the stock is Buy, while BMO Capital Markets gave the stock Outperform rating on October 27, 2023, issuing a price target of $132. UBS on their part issued Buy rating on October 20, 2023.
